Alexandra Canonici

804 total citations
19 papers, 628 citations indexed

About

Alexandra Canonici is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Alexandra Canonici has authored 19 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Alexandra Canonici's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lung Cancer Treatments and Mutations (4 papers). Alexandra Canonici is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lung Cancer Treatments and Mutations (4 papers). Alexandra Canonici collaborates with scholars based in Ireland, United States and France. Alexandra Canonici's co-authors include John Crown, Norma O’Donovan, Laurent Pouyet, Neil A. O’Brien, Frederic André, Véronique Rigot, Virginie Millet, Philippe Naquet, Claude Bagnis and Florent Martin and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Alexandra Canonici

18 papers receiving 621 citations

Peers

Countries citing papers authored by Alexandra Canonici

Since Specialization

Citations

This map shows the geographic impact of Alexandra Canonici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Canonici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Canonici more than expected).

Fields of papers citing papers by Alexandra Canonici

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra Canonici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Canonici. The network helps show where Alexandra Canonici may publish in the future.

Co-authorship network of co-authors of Alexandra Canonici

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Canonici. A scholar is included among the top collaborators of Alexandra Canonici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Canonici. Alexandra Canonici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer 2023 ·PLoS ONE ·Sandra Roche, Patricia Gaule, (unknown), Nupur Mukherjee, (unknown), Neil T. Conlon, Justine Meiller, Denis M. Collins, Alexandra Canonici, (unknown), Alejandra Estepa‐Fernández, Stephen F. Madden, John Crown, Norma O’Donovan, Alex J. Eustace	6
2	Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy 2023 ·British Journal of Cancer ·(unknown), Alfonso Blanco, Stephen F. Madden, Barry Moran, Jean M. Fletcher, (unknown), (unknown), Alex J. Eustace, Martina S.J. McDermott, Alexandra Canonici, Sinéad Toomey, (unknown), Bryan T. Hennessy, Norma O’Donovan, John Crown, Denis M. Collins	6
3	Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A 2020 ·Investigational New Drugs ·Laura Breen, Patricia Gaule, Alexandra Canonici, Naomi Walsh, Denis M. Collins, Mattia Cremona, Bryan T. Hennessy, Michael J. Duffy, John Crown, (unknown), Alex J. Eustace	10
4	Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer 2020 ·Therapeutic Advances in Medical Oncology ·Alexandra Canonici, (unknown), (unknown), (unknown), Sandra Roche, Neil T. Conlon, (unknown), Justine Meiller, Mattia Cremona, (unknown), Bryan T. Hennessy, Alex J. Eustace, Flavio Solca, Norma O’Donovan, John Crown	26
5	EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models 2019 ·Annals of Oncology ·(unknown), (unknown), Alexandra Canonici, John Crown, Denis M. Collins	0
6	Preclinical evaluation targeting both IGF1R and IR in triple negative breast cancer 2019 ·Annals of Oncology ·Alex J. Eustace, Sandra Roche, Nupur Mukherjee, (unknown), Neil T. Conlon, Justine Meiller, Denis M. Collins, Patricia Gaule, Alexandra Canonici, Stephen F. Madden, Norma O’Donovan, John Crown	1
7	The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells 2018 ·Investigational New Drugs ·Alexandra Canonici, (unknown), Neil T. Conlon, Denis M. Collins, Neil A. O’Brien, Naomi Walsh, Alex J. Eustace, Norma O’Donovan, John Crown	19
8	HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer 2018 ·Investigational New Drugs ·Alexandra Canonici, (unknown), Neil T. Conlon, Kasper Pedersen, (unknown), Brigid C. Browne, Neil A. O’Brien, Giuseppe Gullo, Denis M. Collins, Norma O’Donovan, John Crown	21
9	Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells 2017 ·International Journal of Oncology ·Martina S.J. McDermott, Alexandra Canonici, (unknown), Brigid C. Browne, Stephen F. Madden, Neil A. O’Brien, John Crown, Norma O’Donovan	24
10	Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer 2016 ·Annals of Oncology ·Alexandra Canonici, (unknown), (unknown), Mattia Cremona, (unknown), Bryan T. Hennessy, Flavio Solca, John Crown, Norma O’Donovan	4
11	Effect of afatinib alone and in combination with dasatinib in triple-negative breast cancer cell lines. 2014 ·Journal of Clinical Oncology ·(unknown), Alexandra Canonici, Denis M. Collins, John Crown, Norma O’Donovan	2
12	Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer 2013 ·Oncotarget ·Alexandra Canonici, Merel Gijsen, Maeve Mullooly, (unknown), (unknown), Kasper Pedersen, Neil A. O’Brien, Ioannis Roxanis, Jiliang Li, (unknown), Richard S. Finn, Dennis J. Slamon, Patricia M. McGowan, Michael J. Duffy, Norma O’Donovan, John Crown, Anthony Kong	137
13	Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines. 2013 ·Journal of Clinical Oncology ·Alexandra Canonici, (unknown), Brigid C. Browne, Martina S.J. McDermott, Naomi Walsh, John Crown, Norma O’Donovan	5
14	Saccharomyces boulardii Improves Intestinal Epithelial Cell Restitution by Inhibiting αvβ5 Integrin Activation State 2012 ·PLoS ONE ·Alexandra Canonici, (unknown), Carole Siret, Chloé Terciolo, Dorota Czerucka, (unknown), Jacques Marvaldi, Dominique Lombardo, Véronique Rigot, Frederic André	26
15	Effect of neratinib (N) alone and in combination with trastuzumab (T) in HER2-positive breast cancer (BC) cell lines. 2012 ·Journal of Clinical Oncology ·Alexandra Canonici, Kasper Pedersen, Naomi Walsh, John Crown, Norma O’Donovan	7
16	Saccharomyces boulardii Improves Intestinal Cell Restitution through Activation of the α2β1 Integrin Collagen Receptor 2011 ·PLoS ONE ·Alexandra Canonici, Carole Siret, (unknown), Rodolphe Pontier-Bres, Laurent Pouyet, Marie-Pierre Montero, Carole Colin, Dorota Czerucka, Véronique Rigot, Frederic André	35
17	Helicobacter pylori Counteracts the Apoptotic Action of Its VacA Toxin by Injecting the CagA Protein into Gastric Epithelial Cells 2009 ·PLoS Pathogens ·Amanda Oldani, Mireille Cormont, Véronique Hofman, (unknown), (unknown), Alexandra Canonici, Anna Di Sciullo, Patrizia Sommi, Alessia Fabbri, Vittorio Ricci, Patrice Boquet	107
18	Insulin‐like growth factor‐I receptor, E‐cadherin and αv integrin form a dynamic complex under the control of α‐catenin 2007 ·International Journal of Cancer ·Alexandra Canonici, Wim F. A. Steelant, Véronique Rigot, (unknown), (unknown), Erik Bruyneel, Frans van Roy, Françoise Garrouste, Gilbert Pommier, Frederic André	69
19	Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity 2006 ·The Journal of Experimental Medicine ·Carole Berruyer-Pouyet, Laurent Pouyet, Virginie Millet, Florent Martin, (unknown), Alexandra Canonici, Stéphane Garcia, Claude Bagnis, Philippe Naquet, Franck Galland	123

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact